Sanofi (NASDAQ:SNY) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 70.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,785,316 shares of the company's stock after selling 6,527,260 shares during the quarter. Bank of New York Mellon Corp owned about 0.11% of Sanofi worth $134,336,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in SNY. Franklin Resources Inc. lifted its position in Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Natixis Advisors LLC lifted its position in Sanofi by 4.1% during the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company's stock valued at $165,640,000 after purchasing an additional 114,133 shares during the period. JPMorgan Chase & Co. increased its position in Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock valued at $133,172,000 after acquiring an additional 399,301 shares during the last quarter. DAVENPORT & Co LLC raised its position in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock worth $110,715,000 after acquiring an additional 664,455 shares during the period. Finally, Jennison Associates LLC boosted its stake in shares of Sanofi by 938.0% during the 3rd quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ:SNY traded up $2.13 during midday trading on Monday, hitting $56.60. The company's stock had a trading volume of 1,008,833 shares, compared to its average volume of 2,351,113. The company has a market cap of $143.63 billion, a P/E ratio of 22.69, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The business's 50 day simple moving average is $51.65 and its 200 day simple moving average is $52.59. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts forecast that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have commented on SNY. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Sanofi currently has a consensus rating of "Buy" and an average target price of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.